Events & Presentations

Presentations
Date Title
September 25, 2024
Investor Presentation
September 17, 2024
Subgroup Analysis of FOCUS Phase 3 Trial Efficacy Results
June 6, 2022
FOCUS Phase 3 Trial Results: Percutaneous Hepatic Perfusion (PHP) With Melphalan for Patients With Ocular Melanoma Liver Metastases (PHP-OCM-301/301A)
December 2, 2021
Phase 3 FOCUS Trial Results
June 7, 2021
Focus Trial Preliminary Analysis - ASCO 2021

Events and Webcasts